Neumora Therapeutics, Inc.
corporate_fare Company Profile
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 17 items for NMRA at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-08-14, rated 9/10. Across its 17 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for NMRA spans 10-Q, 8-K, DEF 14A, 10-K.
Recent high-impact activity:
- Neumora Flags Going Concern Doubt as Cash Runs Short
- Neumora Names Joshua Pinto CEO as Berns Moves to Executive Chair
- Neumora Names New CEO, Extends Cash Runway to Q3 2027, and Sets Key Pipeline Milestones
- Neumora Reports Favorable Toxicology for NMRA-215, Plans Phase 1 by Year-End
- Neumora Halts Lead Depression Drug, Cuts 35% Staff, Extends Cash Runway to Q3 2027
Financial Snapshot
Short Interest & Short Volume
9.02 days to coverFINRA reported short interest of 6,979,674 shares in NMRA as of the September 15, 2026 settlement, a 13.0% decrease from the prior period — about 9.0 days to cover at its recent average daily volume. On October 2, 2026, 48.2% of NMRA volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.